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Background: SCA28 is an autosomal dominant ataxia associated with AFG3L2 gene mutations. We performed a
whole genome expression profiling using lymphoblastoid cell lines (LCLs) from four SCA28 patients and six
unrelated healthy controls matched for sex and age.
Methods: Gene expression was evaluated with the Affymetrix GeneChip Human Genome U133A 2.0 Arrays and
data were validated by real-time PCR.
Results: We found 66 genes whose expression was statistically different in SCA28 LCLs, 35 of which were up-regulated
and 31 down-regulated. The differentially expressed genes were clustered in five functional categories: (1) regulation
of cell proliferation; (2) regulation of programmed cell death; (3) response to oxidative stress; (4) cell adhesion,
and (5) chemical homeostasis. To validate these data, we performed functional experiments that proved an
impaired SCA28 LCLs growth compared to controls (p < 0.005), an increased number of cells in the G0/G1
phase (p < 0.001), and an increased mortality because of apoptosis (p < 0.05). We also showed that respiratory
chain activity and reactive oxygen species levels was not altered, although lipid peroxidation in SCA28 LCLs
was increased in basal conditions (p < 0.05). We did not detect mitochondrial DNA large deletions. An increase
of TFAM, a crucial protein for mtDNA maintenance, and of DRP1, a key regulator of mitochondrial dynamic
mechanism, suggested an alteration of fission/fusion pathways.
Conclusions: Whole genome expression profiling, performed on SCA28 LCLs, allowed us to identify five
altered functional categories that characterize the SCA28 LCLs phenotype, the first reported in human cells to
our knowledge.
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Spinocerebellar ataxias or SCAs are a heterogeneous
group of autosomal dominant neurodegenerative dis-
eases with an incidence of ~ 1:30,000 and an onset which
is typically in adulthood. At least 30 different subtypes
and 19 causative genes have been reported [1]. For all such
SCA genes, despite a well-described clinical and patho-
logical phenotype, the molecular and cellular events that
underlie neurodegeneration are still poorly understood.
SCA28 is one of the more recently identified forms,
and is associated with mutations in AFG3L2 (ATPase
family gene 3-like 2) on chromosome 18p [2,3]. All mu-
tations so far reported are missense changes, all are lo-
cated in the M41-protease domain of the AFG3L2
protein with the exception of one (p.Asn432Thr) [3-5].
The disease prevalence is around 1.5% among SCA pa-
tients of European descent [2-4]. The AFG3L2 gene en-
codes a subunit of the ATP-dependent metalloprotease
m-AAA (ATPases Associated with a variety of cellular
Activities), located within the inner mitochondrial mem-
brane [6], where it exerts different functions in mito-
chondrial proteins processing, maturation, activation
and quality control, or degradation [7-12]. The m-AAA
displays a hexameric ring structure that in humans can
be a homo-oligomer formed by AFG3L2 only, or a
hetero-oligomer formed by AFG3L2 and Paraplegin
(a paralog of AFG3L2 encoded by the SPG7 gene, whose
loss-of-function causes an autosomal recessive form of her-
editary spastic paraplegia [12,13]). A homozygous AFG3L2
mutation (p.Tyr616Cys) has been detected in two children
affected by an early-onset severe spastic ataxia-neuropathy
syndrome, characterized by severe spasticity, ataxia, and
myoclonic epilepsy [14]. A recent report of SPG7 dominant
mutations in a form of optic atrophy shows that both genes
may give dominant and recessive phenotypes [15].
Several groups have attempted to characterize the bio-
chemical defects caused by alterations in the AFG3L2
protein, albeit no study on human cells has been
reported thus far. Yeast cells lacking the m-AAA com-
plex transfected with mutated AFG3L2 show a respira-
tory defect (i.e. incapacity to grow on a non-fermentable
carbon source) related to a deficiency of respiratory
chain complex IV and proteolytic impairment [3].
ATP production has been evaluated in the brain of
both Afg3l2par/par and Afg3l2Emv66/Emv66 mutant mice,
which are a spontaneous mouse mutant (paralysé) carry-
ing an Arg389Gly substitution in the conserved AAA-
domain of AFG3L2 (Afg3l2par/par), and a null Afg3l2
mouse model with a murine leukemia proviral insertion
in exon 14 (Afg3l2Emv66/Emv66), respectively. In the pres-
ence of different substrates and inhibitors of the respira-
tory chain, results point to an assembly impairment of
complexes I and III [16], while alterations in their
activity and in ATP production were demonstrated ina heterozygous mouse Afg3l2+/Emv66, although with an on-
set at 4-6 months of age [17].
In this study, we characterized the genome-wide ex-
pression profile, and the cellular phenotype of human
lymphoblastoid cell lines (LCLs) derived from SCA28
patients, highlighting alterations in specific pathways
and functions correlated to the disease.
Methods
Cells lines
We obtained lymphoblastoid cell lines (LCLs) derived
from SCA28 patients carrying the p.Gly671Arg (n = 3),
p.Met666Arg (n = 1), p.Met666Val (n = 3), p.Met666Thr
(n = 2), and p.Thr654Ile (n = 1) mutations. Clinical fea-
tures of these patients have been previously described
[4] and are summarized in [Additional file 1]. Fourteen
control LCLs were obtained from the Human Genetics
Foundation of Torino (HuGeF).
LCLs were grown at 37°C and 5% CO2 in RPMI-1640
medium supplemented with 10% heat-inactivated fetal bo-
vine serum, 2 mM L-glutamine, 0.1 mg/ml streptomycin,
and 100 U/ml penicillin.
Whole genome RNA expression profiling
Total RNA was extracted from 5 × 106 LCLs using
the Qiaquick RNA Easy plus extraction kit (Qiagen,
Mannheim, Germany) according to manufacturer's instruc-
tions. A sample of the total RNA was visualized in a 0.6%
TBE 1X/agarose gel and its quality assessed using the
Agilent BioAnalyser 2100 (Agilent, Palo Alto, CA). RNA
was then quantified with a NanoDrop 1000 spectropho-
tometer (Thermo Scientific, Barrington IL, USA).
Whole-genome RNA expression study was performed
on a subgroup of four SCA28 patients, each carrying a
different AFG3L2 mutation (p.Thr654Ile, p.Met666Val,
p. Met666Thr, and p.Gly671Arg). Six unrelated healthy
subjects matched for sex and age at sampling were used
as controls.
For each sample, total RNA (6 μg) was labeled according
to the standard one-cycle amplification and labeling proto-
col developed by Affymetrix (Santa Clara, CA, USA).
Labeled cRNA was hybridized on Affymetrix GeneChip
Human Genome U133A 2.0 Arrays containing probes for
over 18,400 transcripts. Hybridized arrays were stained
and washed on a GeneChip Fluidics Station 450 and then
scanned on a GeneChip Scanner 3000 7G (Affymetrix).
Cell intensity values and probe detection calls were
computed from the raw array data using the Affymetrix
GeneChip Operating Software (GCOS). Further data
processing was performed in the R computing environ-
ment using specific packages from the BioConductor
software project [18]. Robust Multi-Array Average (RMA)
normalization was applied. Normalized data were filtered
based on the Affymetrix detection call, so that only probes
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retained. Probes with low intensity values (less than 100) in
all arrays were also excluded from statistical analysis.
Data were imported into the MultiExperiment Viewer
(MeV) software [19], and statistical analysis was performed
to detect significantly differentially expressed genes in
SCA28 patients versus healthy controls, using two different
tests as implemented within the MeV: Rank Product (RP)
[20] and Significance Analysis of Microarrays (SAM) [21].
RP was run using 100 permutations and a False Discovery
Rate (FDR) of 0.005%. The SAM test was run using 1000
permutations and a FDR of 3%. Differentially expressed
genes were then specifically examined based on their Gene
Ontology annotations [22] and through the use of the
Database for Annotation, Visualization and Integrated Dis-
covery (DAVID) Bioinformatics Resources [23-25].
Validation of data by real-time RT-PCR
Genes to be validated were selected on the basis of three
criteria: (i) an expression level higher than 7, (ii) fold
changes higher than 1.5 or lower than 0.7 in patients vs.
controls, and (iii) the potential interest of the gene in
SCA28 pathogenesis as inferred by its function, the
pathway in which it was involved and/or the functional
similarity with known ataxia-related genes.
Quantitative real time PCR was used to validate array
findings for 11 genes in the same LCLs batches used for
microarray expression profiling (see above). The vali-
dated genes were then tested using a different RNA ex-
traction from the same subjects (4 patients vs. 6 controls)
to obtain a technical replicate. In addition, a third real-time
PCR experiment on the same genes was performed on
LCLs generated from four new different SCA28 patients
obtained later [mutations p.Met666Arg, p.Met666Thr and
p.Met666Val (n = 2)], as biological replicate.
Total RNA was extracted from eight SCA28 patients
and eight healthy controls as described above, and 1 μg
was retrotranscribed using the Transcription First Strand
cDNA synthesis kit (Roche Diagnostics, Mannheim,
Germany). Quantitative real-time RT-PCRs were car-
ried out on an ABI-Prism7500 Fast instrument (Applied
Biosystems) using the Taqman Gene Expression Master
Mix (Applied Biosystems), Universal Probe Library (UPL)
technology (Roche) and according to the manufacturer’s
protocol. Primers and UPL probes used for real time PCR
validation are listed in Additional file 2.
Experimental Ct values were normalized to TATA-
binding protein, used as endogenous control (VIC la-
beled pre-designed TaqMan gene expression assays, TBP,
Hs00427620_m1, Applied Biosystems). Gene expression
was calculated in each sample relative to the mean of
controls, using the delta-delta Ct method as described
elsewhere [26]. Each sample was examined in triplicate
and differences in gene expression of patients relative tocontrols were statistically evaluated by the Student’s
t-test for at least three independent experiments.
Cell growth analysis
Cell growth was determined using the MTT test [Car-
bonyl cyanide p‐(trifluoromethoxy) phenylhydrazone,
3‐(4,5‐dimethylthiazol) 2,5‐ diphenyl-tetrazolium bromide,
Sigma-Aldrich] [27]. The growth of LCLs from six
patients carrying the p.Thr654Ile (n = 1), p.Met666Thr
(n = 1), p.Met666Val (n = 2), p.Met666Arg (n = 1) and
p.Gly671Arg (n = 1) mutations was compared to the
growth of seven LCLs from healthy controls, performing
six replicates for each of the five time-points analyzed (0, 3,
6, 24, and 48 hours). After overnight incubation in RPMI
with 0.5% FCS, 3 × 104 cells for each time-point were
washed twice in PBS solution, the pellet was resuspended
in 1 ml of RPMI supplemented with 10% FCS and seeded
onto 96‐well plates (150 μl/well). At each time-point, 10 μl
of a 5 mg/ml MTT solution were added to each well. A
negative control was included in each experiment to ex-
clude microbial contamination.
After 1 hour incubation at 37°C in the dark the MTT so-
lution was carefully removed, and cells were dissolved in
100 μL of DMSO for 10 minutes at 37°C. Proliferation rate
of cells was determined by measuring the optical density
(OD) of each sample at 570 nm with an ELISA Microplate
Reader Model 680 (Biorad). To confirm growth curves
with a second method, independent of mitochondrial func-
tion, we used a cytoplasmic membrane-dye (Neuro-DiO,
Biotium) whose fluorescence intensity decreases as a con-
sequence of cell divisions. The design of the experiment
was the same as that of the MTT assays, and fluorescence
was analyzed by a FACS Calibur flow cytometer using
CellQuest software (Becton Dickinson, USA).
Analysis of cell cycle
Cell cycle was analyzed by fluorescence labeling of DNA
with Propidium Iodide (PI) [28], a stoichiometric dye,
that binds in proportion to the amount of DNA present
in the cell. LCLs from six healthy controls and six SCA28
patients carrying the p.Thr654Ile (n = 1), p.Met666Thr
(n = 1), p.Met666Val (n = 2), p.Met666aArg (n = 1), and
p.Gly671Arg (n = 1) mutations were compared at three
different time-points (0, 3, and 24 h). Approximately 5 ×
105 cells for each time-point were subjected to density
gradient centrifugation Ficoll-Paque Plus (GE Healthcare,
Piscataway, NJ) to remove any dead cell and debris. Vi-
able cells were collected at the interface and washed with
PBS solution. Cells were synchronized by overnight incu-
bation in RPMI containing 0.5% FCS, washed twice in
PBS and seeded onto a 24-wells plate in 0.5 ml of RPMI
10% FCS at the final concentration of 5 × 105/ well. At
the designed time-points (0, 3 and 24 h), each well was
washed with PBS and resuspended in 1 ml of PBS with
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sample for 45 minutes at 4°C, samples were then rinsed
with PBS, suspended in 0.5 ml of PBS with 0.1% BSA and
5 μl of RNaseA [10 mg/ml], and incubated 30 minutes at
37°C. One μl of PI was added to each sample for 10 mi-
nutes at 4°C in the dark, then cells populations were ana-
lyzed on a FACS Calibur flow cytometer using CellQuest
software (Becton Dickinson).
Analysis of apoptosis
Apoptosis was evaluated by fluorescence-activated cell
sorting (FACS) after Annexin V/propidium iodide (PI)
double staining (Biovision, San Francisco, CA, USA). LCLs
from six healthy controls and six patients carrying the
p.Thr654Ile (n = 1), p.Met666Arg (n = 1), p.Met666Thr
(n = 1), p.Met666Val (n = 2), and p.Gly671Arg (n = 1)
mutations were used [29].
Cells were washed twice with Annexin-Binding Buffer
(ABB) [30], and incubated for 5 minutes in the dark with:
1) ABB alone; 2) Annexin V-FITC; 3) PI; 4) Annexin
V-FITC and PI. Early apoptotic cells were only stained by
Annexin V-FITC, whereas late apoptotic or necrotic cells
were double-stained by Annexin V-FITC and PI. Cells
were analyzed on a FACS Calibur flow cytometer using
CellQuest software (Becton Dickinson). Cells in which
apoptosis was induced by overnight incubation with 1 μM
staurosporine were used as the positive control. To exclude
that increasing apoptosis was due to starvation, the same
experiments were performed without overnight incubation
in RPMI with 0.5% FCS.
ATP synthesis and respiratory chain complex evaluation
Mitochondria were isolated from three SCA28 and three
controls LCLs by differential centrifugation as described
[31]. Ten million cells were homogenized using a glass-
Teflon homogenizer in an isotonic buffer [0.25 M su-
crose, 20 mM 3-(N-morpholino) propanesulfonic acid
(MOPS), pH 7.2, 1 mM EDTA] supplemented with 0.1%
BSA and 0.1 mg/ml digitonin. Cell debris and nuclei
were pelleted twice by centrifugation at 2,500 g for 5 mi-
nute at 4°C. Supernatants were centrifuged at 12,000 g
for 25 min at 4°C and the mitochondrial pellet was
resuspended in isotonic buffer (0.5 M sucrose, 20 mM
MOPS, pH 7.2, 1 mM EDTA).
Respiratory chain activity was evaluated using a proto-
col previously described [16] and adapted to LCLs. In
brief, isolated mitochondria were incubated at 37°C for
30 min in a respiratory buffer (0.25 M sucrose, 20 mM
MOPS, 1 mM EDTA, 5mM inorganic phosphate, 0.1%
BSA, and 1 mM ADP, pH 7.4). The function of each
respiratory chain complex was tested by providing
buffers containing specific substrates and inhibitors.
(1) Buffer 1 (5 mM pyruvate and 1 mM malate) and
(2) buffer 2 (5 mM glutamate and 1 mM malate) were usedto stimulate complex I, II, III, IV, and V-dependent ATP
synthesis. (3) Buffer 3 containing a complex I inhibitor
(1 mM rotenone) and 10 mM succinate, was used to
measure ATP production that is dependent on complex
II, III, IV, and V. Finally, (4) buffer 4 [2 mM antimycin
A -inhibitor of complex III- and 0.1 mM tetramethyl-
p-phenylenediamine (TMPD) / 2 mM ascorbate] was
used to evaluate the ATP level resulting from the ac-
tivity of complex IV and V.
ATP concentration was determined with the luciferin-
luciferase method as described previously [32]. In brief,
isolated mitochondria were lysed with the ATP lysis buf-
fer (200 mM NaOH and 500 nM EDTA), and an aliquot
of the obtained extract was diluted with the ATP dilution
buffer (100 mM NaOH and 500 nM EDTA). Twenty mi-
croliters of this mixture were added to 100 μl of the assay
solution (250 mM glycylglycine, 2 mM EGTA, 2 mM
MgCl2, 0.4 g/L BSA, 7.5 mM DTT, 15 μM luciferin, and 10
μg/ml luciferase), and the ATP content was measured
using a luminometer. Three independent experiments were
performed, and the significance of the means calculated
using two-tailed Student’s t-test.
Quantification of total cellular ATP levels
The amount of cellular ATP was measured by using the
Adenosine 5'-triphosphate (ATP) Bioluminescent Assay
Kit (Sigma-Aldrich, St. Louis, MO, USA), as described
previously [33]. ATP content was measured in duplicate,
according to manufacturer’s instructions, using an appro-
priate internal ATP standard for calibration. Total protein
quantification was performed using classical Bradford
protocol.
Thiobarbituric acid reactive substances (TBARS)
measurement
Lipid peroxidation was evaluated measuring the Thio-
barbituric acid reactive substances (TBARS) levels, fol-
lowing published methods [34]. Cells were washed twice
in PBS and the pellet resuspended in 600 μl of PBS.
Five μl of Triton X-100 and 500 μl of “TBA solution”
(0.375% Thiobarbituric acid and 30% Trichloroacetic
Acid in 0.5 N HCl) were added to 500 μl of cells. Sam-
ples were boiled at 100°C for 20 minutes and quickly
cooled by immersion in an ice bath, and centrifuged at
13000 g for 5 minutes. The absorbance of 300 μL of su-
pernatants was read at 532 nm with a Synergy HT
microplate reader (Bio-Tek Instruments, Winooski, VT),
reading the absorbance at 532 nm. TBARS values were
expressed as nmol/mg proteins.
Reactive Oxygen Species evaluation
Intracellular Reactive Oxygen Species (ROS) levels were
determined by using the fluorescent dye, DCFH-DA,
2,7-dichlorodihydrofluorescein diacetate (5 μM). DCFH
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compound, dichlorofluorescein, which can be analyzed
by flow cytometry. Cells were incubated with DCFH-DA
(5 μM) at 37°C for 30 min, washed twice with PBS, and
then measured on a FACS Calibur flow cytometer using
CellQuest software (Becton Dickinson). Cells treated with
H2O2 (10 μM) were used as the positive control. Three in-
dependent experiments were performed.
Mitochondrial DNA analysis
Evaluation of mtDNA copy number was performed with
an absolute quantitative TaqMan real-time PCR using
the LightCycler480 (Roche), as previously detailed [35].
Long-range PCR was performed to screen for the pres-
ence of mtDNA deletions or rearrangements, as de-
scribed [36].
Western blot
Total proteins were extracted from LCLs of four patients
and four healthy controls, using the RIPA Lysis Buffer
[TrisHCl (50 mM), NaCl (150 mM), Triton (1%)] and
quantified using standard Bradford protocol. Proteins
(20-40 μg) were denaturated for 5 min at 99°C in Laemmli
Buffer (Biorad) and separated by SDS–PAGE (10% or 12%)
and transferred to nitrocellulose membranes (Biorad) in
Tris-Glycine Buffer with 20% methanol. Western Breeze
Kit (Invitrogen) was used for blocking, hybridization,
secondary antibodies, and detection of antibodies, fol-
lowing manufacturer’s instructions. Hybridizations were
performed with primary antibodies against POLγ (Abcam,
ab116049, 1:1000), TFAM (Abcam, ab131607, 1:1000),
VDAC (Abcam, ab15895, 1:700), DRP1 (BD Biosci-
ences, #611112, 1:1000), OPA1 (BD Biosciences, #612606,
1:1000), MFN1 (Abcam, ab57602, 1:1000), MFN2 (Abcam,
ab56889, 1:1000), ATPase-α (BD Bioscience, #612516,
1:1000) and NDUFA9 (LifeSpan Bioscience, LS-C133337
1:1000). Beta-actin antibody (Abcam Ab8227, 1:2000) or
Lamin B1 antibody (Abcam, ab16048, 1:6000) were used as
loading controls.
Part of the Western blot assays (DRP1, OPA1, MFN1,
and MFN2) were performed after synchronization of the
cells, obtained through overnight incubation in RPMI
with 0.5% FCS followed by serum replacement with RPMI
medium supplemented with 10% FCS for 24 hours.
Results
Whole genome expression analysis in SCA28
lymphoblastoid cells
To identify pathways associated with SCA28, we ana-
lyzed whole genome expression profiles in four patients’
LCLs carrying different missense mutations [p.Thr654Ile
(n = 1); p.Met666Thr (n = 1); p.Met666Val (n = 1);
p.Gly671Arg (n = 1)], compared to six LCLs from
healthy individuals matched for sex, ethnic originand age. We used the Affymetrix GeneChip Human
Genome U133A 2.0 Arrays, which allowed to screen
for 18,400 transcripts including 14,500 well-
characterized genes.
With Rank Product analysis we obtained a list of 76
statistically significant differentially expressed probes in
patients vs. controls, 41 of which were up-regulated
(Fold Change – FC = 2.5-10) and 35 down-regulated
(FC = 0.1-0.3). These probes corresponded to 66 differ-
entially expressed genes (35 up-regulated and 31 down-
regulated: one gene may be tested with more than one
probe) (Figure 1A) (GEO accession number GSE42406
and Additional file 3). Microarray analysis did not show
any statistically significant difference in the mean ex-
pression of AFG3L2. The ratio between the expression
of AFG3L2 and his paralog SPG7 was ~1.2 (9.3 vs. 7.7)
both in patients and controls, in line with data previ-
ously obtained in mice nervous tissues, where AFG3L2
is always more expressed than SPG7 [37].
Hierarchical clustering showed that patients’ whole
genome-expression profiles gathered together, with the
exception of patient P3M (mutation p.Met666Val) whose
profile was slightly different (Figure 1A).
We used eleven genes to validate microarray data by
real-time RT-PCR (ADCY1, GPX7, FOXO3, TES, CCDC92,
BLK, FYN, ATF5, NOTCH2, CYB5R2, and DPYD) in
a total of eight SCA28 patients lines. Expression levels
were comparable to those obtained by array profiling
(Figure 1B).
The Significance Analysis of Microarrays (SAM), a
more stringent statistical method, highlighted five out of
the 66 genes resulting from the Rank Product test, all of
which up-regulated: Adenylate cyclase 1 (brain) (ADCY1,
FC = 6.15); Glutathione peroxidase 7 (GPX7, FC = 2.85);
Forkhead box O3 (FOXO3, FC = 2.63); Testis derived tran-
script (3 LIM domains) (TES, FC = 1.48); Coiled-coil do-
main containing 92 (CCDC92, FC = 1.46).
To cluster the 66 deregulated genes for function/cellular
process we integrated the Gene Ontology (GO) classifica-
tion with information available through NCBI databank
[38]. Five major categories were identified (Figure 1C):
(1) regulation of cell proliferation; (2) regulation of pro-
grammed cell death; (3) response to oxidative stress;
(4) cell adhesion, and (5) chemical homeostasis (more de-
tails in Additional file 3).
Cell proliferation, cell cycle and cell viability assays
Given the deregulation of genes involved in cell prolifer-
ation/death, we set up a series of experiments aimed at
evaluating these pathways. Using the MTT and Neuro-
DiO assays, SCA28 LCLs displayed a reduced growth
compared to controls (p < 0.001) (Figure 2A). This ob-
servation is supported by the results of the cell cycle
analysis that showed an increased percentage of cells
Figure 1 Genome-wide expression analysis in SCA28 lymphoblasts. (A) HeatMap representing 76 statistically significant probes differentially
expressed in SCA28 patients (n = 4) vs controls (n = 6): 41 probes were up-regulated (Fold Change – FC = 2.5-10), and 35 down-regulated
(FC = 0.1-0.3). Hierarchical clustering on the left shows that patients’ whole genome profiling clustered together with the exception of the
patient P3F (mutation p.Gly671Arg), whose profile was slightly different. (B) Validation of gene expression levels by real time RT-PCR. Data
obtained from microarray profiling (grey bars) were comparable to those obtained by RT-PCR on seven SCA28 lymphoblastoid cell lines
(black bars with standard error). On the Y-axis, fold change as multiple of the mean value in controls (arbitrarily set to one). On the X-axis, genes tested.
(C) Differentially expressed genes clustered in five major functional categories based on function: (1) regulation of cell proliferation; (2) regulation of
programmed cell death; (3) response to oxidative stress; (4) cell adhesion, and (5) chemical homeostasis. Numbers in red and green boxes
indicate the transcripts up- and down-regulated, respectively. Grey wedge indicate the remaining categories (26 genes downregulated,
and 16 gene upregulated).
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controls. The percentage of cells in G0/G1 phase was
already different at time 0 (72 ± 1.8% of SCA28 vs. 59 ±
2.3% of CTRLs, p = 0.0003) and increased at 3 hours (68 ±
2.1% vs. 49 ± 4.2%, p = 0.0006), and at 24 hours (69 ± 2.1%
vs. 56 ± 1.4%, p = 0.0001) after restoration of nutrients
(Figure 2B).
Cell viability measured by AnnexinV/Propidium Iodide
(PI) double staining showed increased cell death in SCA28
patients with 41 ± 4.2% of viable cells vs. 61 ± 3.6% incontrols LCLs (One-tailed Student’s t-test, p = 0.003;
Figure 2C).
Oxidative stress
Since oxidative stress response was one of the pathways
highlighted by the gene expression analysis, we mea-
sured direct and indirect signs of ROS increase. Quanti-
tative analysis of intracellular ROS levels with the
DCFH-DA test showed that the basal levels of intracel-
lular ROS in SCA28 patients LCLs were comparable to
Figure 2 Cell growth, cell cycle and apoptosis in SCA28 LCLs. (A) Using the MTT assay, SCA28 LCLs displayed a reduced growth compared
to controls (p < 0.001). (B) FACS analysis revealed that patients’ LCLs showed an increased number of cells in G0/G1 phase (> 15%) compared to
control LCLs at any time point considered. (C) AnnexinV/PI FACS analysis showed that 41 ± 4.2% of SCA28 cells were viable, vs. 61 ± 3.6% of
control cells (One-tailed Student’s t-test, p = 0.003).
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ated MDA levels as an indirect parameter of intracellular
oxidative stress measuring the production of lipid perox-
idation markers (TBARS): the results showed a ~2 fold
increased level of TBARS in SCA28 LCLs vs. controls
(Kruskal-Wallis test, p = 0.0014) (Figure 3A). The TBARS
levels in SCA28 LCLs were comparable to those reached
by control cells after incubation with hydrogen peroxide, a
potent inducer of ROS production.
Mitochondrial functionality
To investigate the effects of AFG3L2 missense changes
in mitochondrial metabolism, we analyzed ATP synthesis
both in SCA28 cells and in isolated mitochondria in the
presence of selected substrates and inhibitors. We did
detect neither a significant impairment in ATP synthesis
in isolated mitochondria nor a reduction in the total
ATP cellular content (data not shown).
Next, we assessed the mtDNA copy number by real-
time PCR to exclude mtDNA depletion. No statistically
significant differences were detectable in patients com-
pared to controls and no mtDNA deletions or large
rearrangements were found (data not shown).
We measured the expression levels of six mitochon-
drial proteins representative of respiratory chain com-
plexes or regulators of mtDNA replication/transcription
(i.e., ATPase-α, Core2, NDUFA9, POLG1, SDHA, TFAM,
VDAC). Western blot analysis of Mitochondrial Transcrip-
tion Factor A (TFAM) showed a significant increase of
protein levels compared to controls (Figure 3B), whereas
no differences were appreciable in the other tested proteins
(Additional file 4).
Mitochondrial fission/fusion
We last explored the fission/fusion network in SCA28
LCLs, measuring DRP1, MFN1, MFN2, and OPA1Figure 3 Analysis of lipid peroxidation and mitochondrial function. (A
of ROS was measured in SCA28 LCLs compared to controls (Kruskal-Wallis t
increase level of TBARS suggesting the presence of hidden ROS damages,
activity and total ATP content (not shown). (B) Western blot analysis of TFA
in SCA28 cell lines, suggesting an impairment in mtDNA turnover. (C) The
showed a statistical significant reduction in DRP1 in SCA28 LCLs comparedprotein expression (Additional file 4). Among these, only
DRP1 showed a statistically significant reduction in
SCA28 LCLs compared to controls (two-tailed Student’s
t-test, p = 0.02, Figure 3C).
Discussion
A critical aspect of neurodegenerative disorders studies
in humans is that they are hampered by the difficulty in
obtaining the pathological tissues. In the attempt to
overcome this limitation, other cell types such as fibro-
blasts, lymphocytes, or immortalized LCLs have been
exploited for a wide set of experiments [39,40]. To iden-
tify disease pathways and biomarkers for fast diagnoses,
microarray genome-wide expression technology, often
followed by functional studies, has been used [41].
In this paper, we studied the genomic expression pro-
file of SCA28 patients LCLs and validated the data by
real-time PCR, including in a replication set of patients
and controls LCLs. Differentially expressed transcripts
clustered in five major functional categories: (1) regula-
tion of cell proliferation; (2) regulation of programmed
cell death; (3) response to oxidative stress; (4) cell
adhesion, and (5) chemical homeostasis. Alterations of
these pathways are often reported in neurodegeneration.
Functional experiments confirmed an overall cellular
metabolic impairment. When compared to healthy sub-
jects, SCA28 LCLs showed an impaired growth, and an
increased number of cells in the G0/G1 phase that indi-
cated the activation of the G1 cell cycle checkpoint.
Cell cycle alterations have been demonstrated in sev-
eral CNS diseases including both acute damage and
chronic neurodegenerative disorders [42]. Furthermore,
it has been shown that the transition between G0/G1
and S phases of the cell cycle is marked by the switch
from hyperfused to fragmented mitochondria [43], and
mitochondrial fission is dependent on the increase of) Thiobarbituric Acid Reactive Substances (TBARS), an indirect marker
est, **: p = 0.0014; ns: not significative). SCA28 showed a two-fold
that however are not associated with an anomalous respiratory chain
M (Mitochondrial Transcription Factor A) protein showed an increase
analysis of selected proteins involved in mitochondrial fission/fusion
to controls LCLs (two-tailed t test p = 0.02).
Figure 4 Hypothetical model of the effect of AFG3L2mutations
on LCLs. The m-AAA protease (here depicted as the heteromeric
paraplegin/AFG3L2 isoform) is a hexameric complex within the inner
mitochondrial membrane (IMM), which is involved in protein quality
control. We hypothesize that mutations in AFG3L2 result in an
impairment of m-AAA and are connected with oxidative stress damages
(lipid peroxidation), that lead to cell cycle arrest, increased cell death
and consecutive growth delay. (OMM: Outer Mitochondrial Membrane)
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DRP1 expression highlighted in SCA28 LCLs may
affect the activity of the mitochondrial fusion/fission
machinery and may be related to the cell cycle block in
the G0/G1 phase.
SCA28 cells showed an increased expression of BAG3,
FOXO3 and FYN genes that indicates the attempt
to activate an anti-apoptotic response. This, however,
was not sufficient to rescue these cells, which are
much more prone to undergo apoptotic death that the
control cells.
On the other hand, the impairment of the oxidative
stress metabolic impairment may underpin the cell cycle
anomalies. Accordingly, we found increased expression
of ADCY1, FOXO3, and GPX7, involved in ROS detoxifi-
cation [45-47]. Increased and/or impaired ROS response
is mainly the outcome of an altered mitochondrial func-
tionality, and fits with the mitochondrial localization of
AFG3L2. Moreover, it has been recently demonstrated
that defective mitochondrial metabolism is detrimental
for Purkinje cells, affected in spinocerebellar ataxia [39].
Intracellular ROS measured using the DCFH-DA were
not increased in SCA28 cells, at least in the experimen-
tal condition adopted. However, looking at a long lasting
damage induced by ROS by means of the TBARS ana-
lysis we found increased levels of lipid peroxidation. It is
conceivable that the rapid metabolism of LCLs, along
with the short half-life of ROS, led to a rapid turnover of
oxidative species, masking the direct increase of intracel-
lular ROS but leaving long-term by-products in the form
of peroxidated lipids.
Lipid peroxidation of cell membrane phospholipids
also leads to the production of several highly reactive
carbonyl compounds as by-products, which may form a
variety of toxic adducts including cross-linked products
on amino acids or DNA bases [48]. Literature data have
shown that these products are able to damage mtDNA
and key mitochondrial constituents, including enzymes
involved in mitochondrial respiration [49]. Nonetheless,
we did not detect an altered ATP synthesis in isolated
mitochondria or total cell lysates from SCA28 cells,
in contrast with loss-of-function Afg3l2Emv66/Emv66,
Afg3l2Emv66/+, and Afg3l2par/par mouse models, where
complex I and III deficits were reported [16,17]. Nei-
ther altered mtDNA copy number nor mtDNA dele-
tions/rearrangements were furthermore detected in
SCA28 LCLs, suggesting either that the level of reactive
oxygen species does not trigger major mtDNA damages, or
that LCLs turnover in culture does not allow for such gen-
etic damage accumulation. In fact, it must be underlined
that LCLs are not the ideal model to investigate mitochon-
drial functions, due to the small cytoplasmic percentage
within cells. Nonetheless, these caveats reinforce the
importance of our differential data between cases andcontrols. Interestingly, a comparable number of mtDNA
molecules associated with an increase of TFAM, a crucial
protein for mtDNA maintenance, may suggest an impair-
ment in mtDNA turnover leading to the accumulation of
its ‘histone-like’ protein [50,51].
Besides achieving the goal of characterizing SCA28
LCLs cellular hallmarks, our data allow to speculate about
a possible pathogenic mechanism of SCA28. It is plausible
to think that AFG3L2 mutations likely impair the ma-
turation of m-AAA substrates and/or the turnover of
misfolded proteins leading to a mitochondrial damage
(e.g., excess of fission and/or abnormal mtDNA turnover)
and to an increased oxidative stress (increased lipid pero-
xidation). Extracellular stresses, such as starvation or ther-
mal shock and ageing, may worsen this damage. The last
chance for the cell is to remove damaged mitochondria
“homogenizing” organelle contents through fission/fusion
processes, but if this process is impaired (as it is likely in
SCA28 LCLs) it drives cells towards death (Figure 4).
Other cell types may respond to an AFG3L2 altered
function with a different efficiency and looking at mito-
chondria as an integrated subcellular system, each aspect
of its function can be potentially impaired: bioenergetics,
trafficking, organelle interconnectivity (fission/fusion)
and protein quality control.
Conclusions
In conclusion, whole genome expression profiling, perfor-
med on SCA28 LCLs, allowed us to identify five altered
functional categories that characterize the SCA28 LCLs phe-
notype, the first reported in human cells to our knowledge.
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aspects, such as cell cycle blockage, decreased cell growth
or increased apoptosis characterizing SCA28 cells, may be
used as readout for high-throughput screenings of poten-
tial drugs.
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